Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA and Pembrolizumab for prostate cancer
NCT03658447Phase 2Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jul 2019
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan, pembrolizumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Peter MacCallum Cancer Centre. Started Jul 2019; status: completed.
02
Drugs
lutetium lu 177 vipivotide tetraxetanpembrolizumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03658447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03658447.